What do you study?
malegra customer reviews In a note to investors, Leerink Swann analysts Jason Gerberry, JD, and Christopher W. Kuehnle, JD, said Shire is left with two options: Filing for marketing authorizations based on OPUS-2 results, which they predicted was unlikely to result in approval; or conduct a third Phase III trial, which they said would likely add one year to the development timeline.